Smart sensors could predict falls in older adults with dizziness
NCT ID NCT07751354
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This study evaluates a sensor-based version of the Timed Up and Go test (QTUG) for measuring balance and predicting fall risk in older adults with dizziness (vestibulopathy). Researchers will compare QTUG results with other balance tests, track whether a six-month vestibular rehabilitation program improves balance, and see if the test can predict who will fall within a year. The goal is to determine if QTUG is a reliable tool to help doctors identify those at risk and monitor treatment progress.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vestibular rehabilitation (a program of exercises to improve balance and reduce dizziness)
- What this could lead to
- If the QTUG test proves reliable, it could give doctors a simple, sensor-based way to measure balance problems, predict fall risk, and track whether vestibular rehab is helping older adults with dizziness.
- What could go wrong
- This is an early-stage study, and the QTUG test may not prove more accurate than existing balance tests. The results may not apply to all older adults with dizziness, and the rehab program's benefits are not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENIERE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Royal Hallamshire Hospital
Sheffield, South Yorkshire, S10 2JF, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a precise radiation beam spare balance? a study investigates
- New platform trial takes on NF2 tumors with multiple drug strategies
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?
- Drug combo aims to shrink NF2 tumors and save hearing
- Could this pill ease Meniere's hearing loss and dizziness?
- New hope for acoustic neuroma: direct brain infusion of avastin in early trial